-
1
المؤلفون: Pritchard-Jones, Kathy, Bergeron, Christophe, de Camargo, Beatriz, van den Heuvel-Eibrink, Marry M, Acha, Tomas, Godzinski, Jan, Oldenburger, Foppe, Boccon-Gibod, Liliane, Leuschner, Ivo, Vujanic, Gordan, Sandstedt, Bengt, de Kraker, Jan, van Tinteren, Harm, Graf, Norbert
المساهمون: Øra, Ingrid, Creator
المصدر: The Lancet. 386(9999):64-1156
مصطلحات موضوعية: Adolescent, Antineoplastic Combined Chemotherapy Protocols/adverse effects, Chemotherapy, Adjuvant/adverse effects, Child, Preschool, Dactinomycin/administration & dosage, Doxorubicin/administration & dosage, Female, Humans, Infant, Kaplan-Meier Estimate, Kidney Neoplasms/drug therapy, Male, Neoadjuvant Therapy/adverse effects, Neoplasm Staging, Nephrectomy, Treatment Outcome, Vincristine/administration & dosage, Wilms Tumor/drug therapy, Medicin och hälsovetenskap, Klinisk medicin, Cancer och onkologi, Medical and Health Sciences, Clinical Medicine, Cancer and Oncology
-
2
المؤلفون: Andre M. Murad, Jean-Christophe Pignon, Alain Ravaud, Abdallah Flaifel, Judit Kocsis, Scott S. Tykodi, Yuko Ishii, Shruti Shally Saggi, Sabina Signoretti, Sumanta K. Pal, Thomas Powles, Miriam Ficial, Brian I. Rini, Philippe Barthélémy, Saby George, Osvaldo Arén Frontera, David F. McDermott, Robert J. Motzer, M. Brent McHenry, Michael R. Harrison, Frede Donskov, Toni K. Choueiri, Nizar M. Tannir, Jeronimo R. Rodriguez-Cid
المصدر: Ann Transl Med
Tannir, N M, Signoretti, S, Choueiri, T K, McDermott, D F, Motzer, R J, Flaifel, A, Pignon, J C, Ficial, M, Frontera, O A, George, S, Powles, T, Donskov, F, Harrison, M R, Emy, P B, Tykodi, S S, Kocsis, J, Ravaud, A, Rodriguez-Cid, J R, Pal, S K, Murad, A M, Ishii, Y, Saggi, S S, Brent McHenry, M & Rini, B I 2021, ' Efficacy and safety of nivolumab plus ipilimumab versus sunitinib in first-line treatment of patients with advanced sarcomatoid renal cell carcinoma ', Clinical Cancer Research, vol. 27, no. 1, pp. 78-86 . https://doi.org/10.1158/1078-0432.CCR-20-2063مصطلحات موضوعية: 0301 basic medicine, Cancer Research, medicine.medical_specialty, DOXORUBICIN, Population, Ipilimumab, Protein Serine-Threonine Kinases, Sunitinib/therapeutic use, Gastroenterology, 03 medical and health sciences, 0302 clinical medicine, Renal cell carcinoma, Internal medicine, PD-1, Antineoplastic Combined Chemotherapy Protocols, Post-hoc analysis, Sunitinib, Carcinoma, medicine, Humans, Hippo Signaling Pathway, education, Carcinoma, Renal Cell, education.field_of_study, business.industry, Antineoplastic Combined Chemotherapy Protocols/adverse effects, Nivolumab/adverse effects, medicine.disease, SYSTEMIC THERAPY, Kidney Neoplasms, Confidence interval, Kidney Neoplasms/drug therapy, Editorial Commentary, Nivolumab, 030104 developmental biology, ANTIBODY, GEMCITABINE, Oncology, 030220 oncology & carcinogenesis, Carcinoma, Renal Cell/drug therapy, SURVIVAL, Ipilimumab/adverse effects, Immunotherapy, business, medicine.drug
URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e83ef4fae16505a538074156c51ab25a
https://doi.org/10.1158/1078-0432.ccr-20-2063 -
3
المؤلفون: Toni K. Choueiri, Howard Gurney, David F. McDermott, Christian Kollmannsberger, Michael A. Carducci, Martin Eduardo Richardet, M. Brent McHenry, Elizabeth R. Plimack, Fabio A.B. Schutz, David Cella, Nizar M. Tannir, Frede Donskov, Bernard Escudier, John Wagstaff, Yoshihiko Tomita, Robert J. Motzer, Satoshi Fukasawa, Shruti Shally Saggi, Saby George, Giuseppe Procopio, Christine Chevreau, Hans J. Hammers, Thomas Gauler, Daniel Castellano, Jeffrey A. Sosman, James Larkin, Ajjai Alva, Sandhya Srinivas, Katriina Peltola, Scott S. Tykodi, Stéphane Oudard
المصدر: Cancer
Motzer, R J, Escudier, B, George, S, Hammers, H J, Srinivas, S, Tykodi, S S, Sosman, J A, Plimack, E R, Procopio, G, McDermott, D F, Castellano, D, Choueiri, T K, Donskov, F, Gurney, H, Oudard, S, Richardet, M, Peltola, K, Alva, A S, Carducci, M, Wagstaff, J, Chevreau, C, Fukasawa, S, Tomita, Y, Gauler, T C, Kollmannsberger, C K, Schutz, F A, Larkin, J, Cella, D, McHenry, M B, Saggi, S S & Tannir, N M 2020, ' Nivolumab versus everolimus in patients with advanced renal cell carcinoma : Updated results with long-term follow-up of the randomized, open-label, phase 3 CheckMate 025 trial ', Cancer, vol. 126, no. 18, pp. 4156-4167 . https://doi.org/10.1002/cncr.33033مصطلحات موضوعية: CheckMate 025, Male, Oncology, Cancer Research, Medizin, immune checkpoint inhibitor, DOSE RECOMBINANT INTERLEUKIN-2, 0302 clinical medicine, Renal cell carcinoma, Antineoplastic Combined Chemotherapy Protocols, Clinical endpoint, Medicine, 030212 general & internal medicine, Everolimus/pharmacology, Hazard ratio, Kidney Neoplasms, 3. Good health, Kidney Neoplasms/drug therapy, Nivolumab, Treatment Outcome, Tolerability, SAFETY, 030220 oncology & carcinogenesis, SURVIVAL, Female, medicine.drug, medicine.medical_specialty, Antineoplastic Combined Chemotherapy Protocols/pharmacology, previously treated, Article, 03 medical and health sciences, Nivolumab/pharmacology, Internal medicine, Humans, Everolimus, Adverse effect, Carcinoma, Renal Cell, nivolumab, business.industry, everolimus, medicine.disease, LIFE, Carcinoma, Renal Cell/drug therapy, business, Kidney cancer, advanced renal cell carcinoma (aRCC), Follow-Up Studies
-
4
المؤلفون: Chun L. Gan, Daniel E. Meyers, Heidi A. I. Grosjean, Aliyah Pabani, Tina Cheng, Toni K. Choueiri, Sumanta K. Pal, Daniel Y.C. Heng, Naveen S. Basappa, Frede Donskov, Michael Sander, Lori Wood, Igor Stukalin, Shaan Dudani, S. Dolter, Siddhartha Goutam, Connor Wells, Jose Gerard Monzon, Benjamin W. Ewanchuk, Don Morris
المصدر: Gan, C L, Stukalin, I, Meyers, D E, Dudani, S, Grosjean, H A I, Dolter, S, Ewanchuk, B W, Goutam, S, Sander, M, Wells, C, Pabani, A, Cheng, T, Monzon, J, Morris, D, Basappa, N S, Pal, S K, Wood, L A, Donskov, F, Choueiri, T K & Heng, D Y C 2021, ' Outcomes of patients with solid tumour malignancies treated with first-line immuno-oncology agents who do not meet eligibility criteria for clinical trials ', European Journal of Cancer, vol. 151, pp. 115-125 . https://doi.org/10.1016/j.ejca.2021.04.004
مصطلحات موضوعية: 0301 basic medicine, Oncology, Male, Cancer Research, Lung Neoplasms, Skin Neoplasms, Time Factors, Databases, Factual, Carcinoma, Non-Small-Cell Lung/drug therapy, medicine.medical_treatment, Eligibility Determination, 0302 clinical medicine, RENAL-CELL CARCINOMA, Renal cell carcinoma, Carcinoma, Non-Small-Cell Lung, Neoplasms, Clinical outcomes, Skin Neoplasms/drug therapy, IMDC, METASTATIC MELANOMA, Melanoma/drug therapy, Immune Checkpoint Inhibitors, Melanoma, education.field_of_study, Clinical Trials as Topic, CHEMOTHERAPY, Middle Aged, CANCER, Kidney Neoplasms, Kidney Neoplasms/drug therapy, Treatment Outcome, 030220 oncology & carcinogenesis, SURVIVAL, Female, Immunotherapy, medicine.medical_specialty, Real-world patients, RANDOMIZED CONTROLLED-TRIALS, Population, 03 medical and health sciences, Trial eligibility, Immune Checkpoint Inhibitors/adverse effects, Internal medicine, medicine, Humans, education, Lung cancer, PEMBROLIZUMAB, Lung Neoplasms/drug therapy, Carcinoma, Renal Cell, Retrospective Studies, Aged, Solid tumour, Performance status, business.industry, Non–small-cell lung cancer, IPILIMUMAB, Patient Selection, Clinical trial ineligible, Immuno-oncology, medicine.disease, Neoplasms/drug therapy, Clinical trial, 030104 developmental biology, COMBINED NIVOLUMAB, Carcinoma, Renal Cell/drug therapy, business, Non-small-cell lung cancer, REAL-WORLD
وصف الملف: application/pdf
URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cb68feab4d3e27cdcf4e38239ab4d0c5
https://pure.au.dk/portal/da/publications/outcomes-of-patients-with-solid-tumour-malignancies-treated-with-firstline-immunooncology-agents-who-do-not-meet-eligibility-criteria-for-clinical-trials(049edcae-1ed9-4e12-b16e-97de3ae12c00).html -
5دورية أكاديمية
المؤلفون: Motzer, Robert, Alekseev, Boris, Rha, Sun-Young, Porta, Camillo, Eto, Masatoshi, Powles, Thomas, Grünwald, Viktor, Hutson, Thomas E, Kopyltsov, Evgeny, Méndez-Vidal, María J, Kozlov, Vadim, Alyasova, Anna, Hong, Sung-Hoo, Kapoor, Anil, Alonso Gordoa, Teresa, Merchan, Jaime R, Winquist, Eric, Maroto, Pablo, Goh, Jeffrey C, Kim, Miso, Gurney, Howard, Patel, Vijay, Peer, Avivit, Procopio, Giuseppe, Takagi, Toshio, Melichar, Bohuslav, Rolland, Frederic, De Giorgi, Ugo, Wong, Shirley, Bedke, Jens, Schmidinger, Manuela, Dutcus, Corina E, Smith, Alan D, Dutta, Lea, Mody, Kalgi, Perini, Rodolfo F, Xing, Dongyuan, Choueiri, Toni K, CLEAR Trial Investigators
المساهمون: Gennigens, Christine
المصدر: New England Journal of Medicine, 384 (14), 1289 - 1300 (2021-04-08)
مصطلحات موضوعية: Antibodies, Monoclonal, Humanized, Antineoplastic Agents, Phenylurea Compounds, Programmed Cell Death 1 Receptor, Protein Kinase Inhibitors, Quinolines, Everolimus, pembrolizumab, lenvatinib, Sunitinib, Adult, Aged, Aged, 80 and over, Antibodies, Monoclonal, Humanized/administration & dosage, Antibodies, Monoclonal, Humanized/adverse effects, Antineoplastic Agents/adverse effects, Antineoplastic Agents/therapeutic use, Antineoplastic Combined Chemotherapy Protocols/adverse effects, Antineoplastic Combined Chemotherapy Protocols/therapeutic use, Carcinoma, Renal Cell/drug therapy, Carcinoma, Renal Cell/mortality, Everolimus/administration & dosage, Everolimus/adverse effects, Female, Humans, Kidney Neoplasms/drug therapy, Kidney Neoplasms/mortality, Male, Middle Aged, Phenylurea Compounds/administration & dosage, Phenylurea Compounds/adverse effects, Programmed Cell Death 1 Receptor/antagonists & inhibitors, Progression-Free Survival, Protein Kinase Inhibitors/therapeutic use, Quinolines/administration & dosage, Quinolines/adverse effects, Sunitinib/adverse effects, Sunitinib/therapeutic use, Survival Analysis, Antineoplastic Combined Chemotherapy Protocols, Carcinoma, Renal Cell, Kidney Neoplasms, Medicine (all), General Medicine, Human health sciences, Oncology, Sciences de la santé humaine, Oncologie
Relation: http://www.nejm.org/doi/pdf/10.1056/NEJMoa2035716; urn:issn:0028-4793; urn:issn:1533-4406
URL الوصول: https://orbi.uliege.be/handle/2268/300816
-
6
المؤلفون: David F. McDermott, Jae-Lyun Lee, Georg A. Bjarnason, James M. G. Larkin, Rustem A. Gafanov, Mark D. Kochenderfer, Niels Viggo Jensen, Frede Donskov, Jahangeer Malik, Alexandr Poprach, Scott S. Tykodi, Teresa Alonso-Gordoa, Daniel C. Cho, Poul F. Geertsen, Miguel Angel Climent Duran, Christopher DiSimone, Rachel Kloss Silverman, Rodolfo F. Perini, Charles Schloss, Michael B. Atkins
المصدر: McDermott, D F, Lee, J L, Bjarnason, G A, Larkin, J M G, Gafanov, R A, Kochenderfer, M D, Jensen, N V, Donskov, F, Malik, J, Poprach, A, Tykodi, S S, Alonso-Gordoa, T, Cho, D C, Geertsen, P F, Climent Duran, M A, DiSimone, C, Silverman, R K, Perini, R F, Schloss, C & Atkins, M B 2021, ' Open-Label, Single-Arm Phase II Study of Pembrolizumab Monotherapy as First-Line Therapy in Patients With Advanced Clear Cell Renal Cell Carcinoma ', Journal of clinical oncology : official journal of the American Society of Clinical Oncology, vol. 39, no. 9, pp. 1020-1028 . https://doi.org/10.1200/JCO.20.02363
McDermott, D F, Lee, J L, Bjarnason, G A, Larkin, J M G, Gafanov, R A, Kochenderfer, M D, Jensen, N V, Donskov, F, Malik, J, Poprach, A, Tykodi, S S, Alonso-Gordoa, T, Cho, D C, Geertsen, P F, Climent Duran, M A, DiSimone, C, Silverman, R K, Perini, R F, Schloss, C & Atkins, M B 2021, ' Open-Label, Single-Arm Phase II Study of Pembrolizumab Monotherapy as First-Line Therapy in Patients With Advanced Clear Cell Renal Cell Carcinoma ', Journal of Clinical Oncology, vol. 39, no. 9, pp. 1020-1028 . https://doi.org/10.1200/JCO.20.02363مصطلحات موضوعية: Adult, Male, 0301 basic medicine, Cancer Research, Non-Randomized Controlled Trials as Topic, education, Antibodies, Monoclonal, Humanized, 03 medical and health sciences, Antineoplastic Agents, Immunological, 0302 clinical medicine, Humans, Antineoplastic Agents, Immunological/therapeutic use, Carcinoma, Renal Cell, Aged, Aged, 80 and over, Middle Aged, Prognosis, Kidney Neoplasms, Survival Rate, Kidney Neoplasms/drug therapy, 030104 developmental biology, Antibodies, Monoclonal, Humanized/therapeutic use, Oncology, 030220 oncology & carcinogenesis, Carcinoma, Renal Cell/drug therapy, Female, Follow-Up Studies
وصف الملف: application/pdf
URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::df891535cd8598712754ea270af1095c
https://findresearcher.sdu.dk:8443/ws/files/181944398/jco.20.02363.pdf -
7
المؤلفون: Subrina Farah, Ziad Bakouny, Toni K. Choueiri, Frede Donskov, Daniel Y.C. Heng, Aly-Khan A. Lalani, Shaan Dudani
المصدر: JAMA Oncol
Lalani, A K A, Bakouny, Z, Farah, S, Donskov, F, Dudani, S, Heng, D Y C & Choueiri, T K 2021, ' Assessment of immune checkpoint inhibitors and genomic alterations by body mass index in advanced renal cell carcinoma ', JAMA Oncology, vol. 7, no. 5, pp. 773-775 . https://doi.org/10.1001/jamaoncol.2021.0019مصطلحات موضوعية: Cancer Research, business.industry, Immune checkpoint inhibitors, MEDLINE, Genomics, biochemical phenomena, metabolism, and nutrition, medicine.disease, Genome, Kidney Neoplasms, Body Mass Index, Kidney Neoplasms/drug therapy, Text mining, Oncology, Renal cell carcinoma, Carcinoma, Renal Cell/drug therapy, Cancer research, Research Letter, Medicine, Humans, business, Body mass index, Carcinoma, Renal Cell, Immune Checkpoint Inhibitors, Cohort study
URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5b0f12d3ce8ea9dbc648354c3a65db23
https://europepmc.org/articles/PMC7934079/ -
8
المؤلفون: Bohuslav Melichar, Hong Zhang, Frede Donskov, Sergei Varlamov, Christian Doehn, Agnieszka Michael, Ray McDermott, Toni K. Choueiri, Simon Chowdhury, M. Neil Reaume, Evgeny Kopyltsov, Paola Aimone, Robert J. Motzer, Marine Gross-Goupil, Arnulf Stenzl, Paul Russo, Cora N. Sternberg, Brian I. Rini, Naomi B. Haas, Ho Yeong Lim, Milada Zemanova, Lori Wood, Miguel Izquierdo, Jae-Lyun Lee
المصدر: Motzer, R J, Russo, P, Haas, N, Doehn, C, Donskov, F, Gross-Goupil, M, Varlamov, S, Kopyltsov, E, Lee, J L, Lim, H Y, Melichar, B, Zemanova, M, Rini, B, Choueiri, T K, Wood, L, Reaume, M N, Stenzl, A, Chowdhury, S, McDermott, R, Michael, A, Izquierdo, M, Aimone, P, Zhang, H & Sternberg, C N 2021, ' Adjuvant Pazopanib Versus Placebo After Nephrectomy in Patients With Localized or Locally Advanced Renal Cell Carcinoma : Final Overall Survival Analysis of the Phase 3 PROTECT Trial ', European Urology, vol. 79, no. 3, pp. 334-338 . https://doi.org/10.1016/j.eururo.2020.12.029
مصطلحات موضوعية: medicine.medical_specialty, Indazoles, Urology, medicine.medical_treatment, 030232 urology & nephrology, Phases of clinical research, Tyrosine kinase inhibitor, Placebo, Nephrectomy, Disease-Free Survival, Pazopanib, 03 medical and health sciences, 0302 clinical medicine, Renal cell carcinoma, Interquartile range, medicine, Adjuvant therapy, Neoplasm Recurrence, Local/prevention & control, Humans, Carcinoma, Renal Cell, Sulfonamides, business.industry, Hazard ratio, medicine.disease, Kidney Neoplasms, HIGH-RISK, Kidney Neoplasms/drug therapy, Pyrimidines, 030220 oncology & carcinogenesis, Carcinoma, Renal Cell/drug therapy, Neoplasm Recurrence, Local, business, medicine.drug
URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e65985be16fd652ec1915b66d0f0749c
https://pure.au.dk/portal/da/publications/adjuvant-pazopanib-versus-placebo-after-nephrectomy-in-patients-with-localized-or-locally-advanced-renal-cell-carcinoma(d58e9d29-c537-477e-8912-ed7748cfa5de).html -
9
المؤلفون: Calandrini, Camilla, Schutgens, Frans, Oka, Rurika, Margaritis, Thanasis, Candelli, Tito, Mathijsen, Luka, Ammerlaan, Carola, van Ineveld, Ravian L, Derakhshan, Sepide, de Haan, Sanne, Dolman, Emmy, Lijnzaad, Philip, Custers, Lars, Begthel, Harry, Kerstens, Hindrik H D, Visser, Lindy L, Rookmaaker, Maarten, Verhaar, Marianne, Tytgat, Godelieve A M, Kemmeren, Patrick, de Krijger, Ronald R, Al-Saadi, Reem, Pritchard-Jones, Kathy, Kool, Marcel, Rios, Anne C, van den Heuvel-Eibrink, Marry M, Molenaar, Jan J, van Boxtel, Ruben, Holstege, Frank C P, Clevers, Hans, Drost, Jarno, UU BETA RESEARCH, Faculteit Diergeneeskunde
المساهمون: Paediatric Oncology, CCA - Cancer Treatment and Quality of Life, Hubrecht Institute for Developmental Biology and Stem Cell Research, UU BETA RESEARCH, Faculteit Diergeneeskunde
المصدر: Nature Communications, 11(1). Nature Publishing Group
Nature Communications, Vol 11, Iss 1, Pp 1-14 (2020)
Nature communications, 11(1):1310. Nature Publishing Group
Nature Communicationsمصطلحات موضوعية: 0301 basic medicine, Male, Pathology, Renal Cell/drug therapy, Genotyping Techniques, Cell Culture Techniques, General Physics and Astronomy, Cell Culture Techniques/methods, Nephroma, Mesoblastic/drug therapy, Stem cells, Kidney, Drug Screening Assays, 0302 clinical medicine, Kidney/pathology, Tumor Cells, Cultured, RNA-Seq, Precision Medicine, lcsh:Science, Child, Rhabdoid Tumor/drug therapy, Cancer, Biological Specimen Banks, Netherlands, Adult stem cells, Cultured, Multidisciplinary, Precision Medicine/methods, Biobank, Kidney Neoplasms, Tumor Cells, 3. Good health, Organoids, Gene Expression Regulation, Neoplastic, Mesoblastic/drug therapy, Kidney Neoplasms/drug therapy, 030220 oncology & carcinogenesis, Child, Preschool, Female, Single-Cell Analysis, medicine.medical_specialty, Stromal cell, Adolescent, Science, Antitumor/methods, Drug Screening Assays, Antitumor/methods, Transfection, Wilms Tumor, Article, General Biochemistry, Genetics and Molecular Biology, Paediatric cancer, 03 medical and health sciences, Genetic Heterogeneity, Young Adult, medicine, Organoid, Carcinoma, Humans, Nephroma, Kidney tumour, Nephroma, Mesoblastic, Cancer models, Preschool, Carcinoma, Renal Cell, Rhabdoid Tumor, Neoplastic, Whole Genome Sequencing, Genetic heterogeneity, business.industry, Infant, General Chemistry, DNA Methylation, medicine.disease, Organoids/pathology, 030104 developmental biology, Gene Expression Regulation, Carcinoma, Renal Cell/drug therapy, Wilms Tumor/drug therapy, lcsh:Q, Drug Screening Assays, Antitumor, business, Kidney cancer
وصف الملف: application/pdf
-
10
المؤلفون: Frede Donskov, Carina K. Hermansen
المصدر: Hermansen, C K & Donskov, F 2021, ' Outcomes based on age in patients with metastatic renal cell carcinoma treated with first line targeted therapy or checkpoint immunotherapy : Older patients more prone to toxicity ', Journal of Geriatric Oncology, vol. 12, no. 5, pp. 827-833 . https://doi.org/10.1016/j.jgo.2020.12.008
مصطلحات موضوعية: Oncology, medicine.medical_treatment, Tyrosine kinase inhibitor, Immune checkpoint inhibitor, urologic and male genital diseases, Tyrosine-kinase inhibitor, Targeted therapy, 0302 clinical medicine, EVEROLIMUS, Renal cell carcinoma, Medicine, 030212 general & internal medicine, ELDERLY-PATIENTS, COMPREHENSIVE GERIATRIC ASSESSMENT, Kidney Neoplasms, Kidney Neoplasms/drug therapy, Treatment Outcome, 030220 oncology & carcinogenesis, Older adults, SAFETY, Toxicity, SURVIVAL, Immunotherapy, Tyrosine kinase, POSITION PAPER, medicine.medical_specialty, medicine.drug_class, DATABASE, First line, CANCER-PATIENTS, Protein Kinase Inhibitors/adverse effects, Disease-Free Survival, 03 medical and health sciences, INTERNATIONAL-SOCIETY, Internal medicine, Humans, Metastatic RCC, Carcinoma, Renal Cell, Protein Kinase Inhibitors, Dose Modification, Aged, Retrospective Studies, business.industry, medicine.disease, EFFICACY, Immunotherapy/adverse effects, Carcinoma, Renal Cell/drug therapy, Geriatrics and Gerontology, business
وصف الملف: application/pdf
Full Text via ClinicalKey